Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

Wils, J.; Klein, H. O.; Wagener, D. J. Th.; Bleiberg, Harry; Reis, H. E.; Korsten, F. W.; Conroy, T.; Fickers, M. M. F.; Leyvraz, Serge; Buyse, Marc

doi:10.1200/jco.1991.9.5.827

Cited by 372 publications

(146 citation statements)

References 3 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…Similarly, alopecia was a rare side effect when compared with anthracyclines or etoposide-based regimens. The efficacy of this FOLFOX treatment was not different from that observed in phase II -III studies with other second-or third-generation polychemotherapy regimens in AGC (Lacave et al, 1991;Wils et al, 1991;Kelsen et al, 1992;Kim et al 1993;Rougier et al, 1994;Vanhoefer et al, 2000). Interestingly, the median TTP and OS observed in our study population are similar to those reported in a prospectively randomised study comparing ECF with the standard regimen FAMTX (Webb et al, 1997).…”

Section: Discussionsupporting

confidence: 82%

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

et al. 2005

View full text Add to dashboard Cite

The aim of the study was to assess the toxicity and the clinical activity of biweekly oxaliplatin in combination with infusional 5-fluorouracil (5-FU) and folinic acid (FA) administered every 2 weeks (FOLFOX-4 regimen) in patients with advanced gastric cancer (AGC). A total of 61 previously untreated AGC patients were treated with oxaliplatin 85 mg m À2 on day 1, FA 200 mg m À2 as a 2 h infusion followed by bolus 5-FU 400 mg m À2 and a 22 h infusion of 5-FU 600 mg m À2 , repeated for 2 consecutive days every 2 weeks. All patients were assessable for toxicity and response to treatment. Four (7%) complete responses and 19 partial responses were observed (overall response rate, 38%). Stable disease was observed in 22 (36%) patients, with progressive disease in the other six (10%) patients. Median time to progression (TTP) and median overall survival (OS) were 7.1 and 11.2 months, respectively. National Cancer Institute Common Toxicity Criteria grade 3 and 4 haematologic toxicities were neutropenia, anaemia and thrombocytopenia in 36, 10 and 5% of the patients, respectively. Grade 3 peripheral neuropathy was recorded in three (5%) patients. FOLFOX-4 is an active and well-tolerated chemotherapy. Response rate (RR), TTP and OS were comparable with those of other oxaliplatin-based regimens, suggesting a role for this combination in gastric cancer.

show abstract

Section: Discussionsupporting

confidence: 82%

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Intravenous 5FU infusion [10] or in combination with other anticancer drugs, FAM [11], FAMTX [7] have been used for chemotherapy of advanced gastric cancer. Recently, Ajani reported that DCF therapy (a combination chemotherapy using docetaxel, CDDP and 5FU) showed a significant better survival than CF (CDDP þ 5FU) therapy [12].…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery

Yonemura¹,

Endou

Shinbo

et al. 2009

Journal of Surgical Oncology

116

112

View full text Add to dashboard Cite

There is no standard treatment for peritoneal carcinomatosis (PC) from gastric cancer. New bidirectional chemotherapy (neoadjuvant intraperitoneal-systemic chemotherapy protocol (NIPS)) was developed. The aim of the present study was to assess the safety and efficacy of NIPS and to show the selection for cytoreductive surgery on PC from gastric cancer. Seventy-nine patients with PC from gastric cancer were treated with NIPS. A peritoneal port system was introduced into the abdominal cavity. The peritoneal wash cytological examination through a port was done before and after NIPS. The patients were treated with oral TS-1 twice a daily for 21 days, followed by a 1-week rest. On day 1, 8, and 15 from the start of oral TS-1 administration, 30 mg/m 2 of Docetaxel and 30 mg/m 2 of cisplatinum with 500 ml of saline were introduced into the peritoneal cavity through the port. A median course of oral TS-1 was 2.1 course and a median time of IP chemoterapy was 5.8. Peritoneal free cancer cells (PFCCs) had been detected in 65 (82.2%) patients before NIPS, and the positive cytology changed to be negative in 41 (63.0%) patients after NIPS. After NIPS, 41 patients underwent laparotomy, and complete cytoreduction was done in 32 (78%) patients. Complete cytoreduction was done in 27 (51.9%) of 52 patients with negative cytology but in only 4 (14.8%) of 27 patients with positive cytology (P < 0.001). Patients with negative cytology after NIPS survived significantly longer than those with positive cytology. The adverse effects after NIPS were mild and there was no treatment-related deaths. The grade 3/4 hematological adverse effects were found in 2 (2.6%) patients. Grade 3 renal toxicity and port site infection was found in three patients, respectively. NIPS using a port system is a safe and effective treatment for PC. Peritoneal wash cytology through a port system is a good indicator to select the patients to perform cytoreductive surgery.

show abstract

“…These results recapitulated the favorable antitumor effects and survival outcomes reported in the previous phase II study (response rate, 17/29 [59%]; MST, 322 days). 13 Considering that MSTs in other clinical trials of chemotherapy for advanced gastric cancer have ranged from 7 to 10 months, 8,[20][21][22] it appears that this regimen may yield favorable survival rates, even in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

et al. 2001

View full text Add to dashboard Cite

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group.

Cited by 372 publications

References 3 publications

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery

Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice

Contact Info

Product

Resources

About